GlobeNewsWire
15 Dec 2025, 17:39 UTC · 40w ago
Verdict
Headline takes no side. We score AB +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 85% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
AB Science has received regulatory approval to initiate the third stage of the Phase I/II clinical trial (AB18001), combining AB8939 with venetoclax for refractory and relapsed AML.
More positive than 92% of claims this week
Preclinical data published on bioRxiv indicates AB8939 can eradicate leukemic stem cells and overcome multidrug resistance pathways in AML.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 77% of claims this week
AB8939 has received orphan drug designation from both the FDA and EMA, providing 7 and 10 years of marketing exclusivity respectively.
More positive than 63% of claims this week
The company holds intellectual property for AB8939 through 2036, with potential extensions reaching 2044 for specific patient subpopulations.
More positive than 51% of claims this week
Which stocks this story touches
More positive than 85% of ticker scores this week
The company announced positive preclinical research findings and regulatory approval to advance clinical trials for its drug candidate AB8939.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
37m ago
−9.4%
Price is moving against the score
$36.19 vs $39.96 close before publication (Dec 12) · not market-adjusted
AB chart →